Find Acoramidis Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ag10 hydrochloride, Ag-10 hydrochloride, Alxn2060 hydrochloride, Acoramidis (hydrochloride), Alxn-2060 hydrochloride, Vy9c88c2nv
Molecular Formula
C15H18ClFN2O3
Molecular Weight
328.76  g/mol
InChI Key
MGFZEARHINUOMX-UHFFFAOYSA-N
FDA UNII
VY9C88C2NV

Acoramidis Hydrochloride
1 2D Structure

Acoramidis Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid;hydrochloride
2.1.2 InChI
InChI=1S/C15H17FN2O3.ClH/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16;/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20);1H
2.1.3 InChI Key
MGFZEARHINUOMX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F.Cl
2.2 Other Identifiers
2.2.1 UNII
VY9C88C2NV
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Ag10 Hydrochloride

2. Ag-10 Hydrochloride

3. Alxn2060 Hydrochloride

4. Acoramidis (hydrochloride)

5. Alxn-2060 Hydrochloride

6. Vy9c88c2nv

7. Acoramidis Hydrochloride [usan]

8. 2242751-53-5

9. Benzoic Acid, 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluoro-, Hydrochloride (1:1)

10. Unii-vy9c88c2nv

11. Chembl4650226

12. Schembl20475239

13. Acoramidis Hydrochloride [jan]

14. Hy-109165a

15. Cs-0143619

16. 3-(3-(3-5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic Acid Hydrochloride

2.4 Create Date
2018-12-15
3 Chemical and Physical Properties
Molecular Weight 328.76 g/mol
Molecular Formula C15H18ClFN2O3
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass328.0989983 g/mol
Monoisotopic Mass328.0989983 g/mol
Topological Polar Surface Area75.2 Ų
Heavy Atom Count22
Formal Charge0
Complexity356
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

HRV Global Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

03

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo
Not Confirmed
arrow

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Indo Livestock Expo
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

04

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo
Not Confirmed
arrow

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Indo Livestock Expo
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

IFT FIRST
Not Confirmed
arrow
arrow
IFT FIRST
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

NDC Package Code : 59116-5911

Start Marketing Date : 2021-12-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

IFT FIRST
Not Confirmed
arrow
arrow
IFT FIRST
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

NDC Package Code : 59116-5910

Start Marketing Date : 2021-12-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Acoramidis

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Acoramidis

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641753000,"product":"ACORAMIDIS (CAS#1446711-81-4)","address":"12th floor,Commerz II, International Business Park, Oberoi","city":"Goregaon East","supplier":"EOS BIOTECH CO LTD","supplierCountry":"CHINA","foreign_port":"#N\/A","customer":"TEVA API INDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"75000","totalValueFC":"7591.3","currency":"USD","unitRateINR":"5655000","date":"10-Jan-2022","totalValueINR":"565500","totalValueInUsd":"7591.3","indian_port":"DELHI AIR","hs_no":"29331999","bill_no":"7019214","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"12th floor,Commerz II, International Business Park, Oberoi"}]
10-Jan-2022
10-Jan-2022
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Beyonttra

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: HealthCare Royalty

Deal Size: $300.0 million Upfront Cash: $300.0 million

Deal Type: Agreement June 30, 2025

blank

01

IFT FIRST
Not Confirmed
IFT FIRST
Not Confirmed

Details : Beyonttra (acoramidis hydrochloride) is an orally administered near-complete stabilizer of TTR for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy.

Product Name : Beyonttra

Product Type : Other Small Molecule

Upfront Cash : $300.0 million

June 30, 2025

blank

Details:

Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: Attruby

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 13, 2025

blank

02

IFT FIRST
Not Confirmed
IFT FIRST
Not Confirmed

Details : Attruby (acoramidis) is a transthyretin stabilizer being investigated for the treatment of younger patients with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).

Product Name : Attruby

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 13, 2025

blank

Details:

Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Beyonttra

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 28, 2025

blank

03

IFT FIRST
Not Confirmed
IFT FIRST
Not Confirmed

Details : Beyonttra is an orally administered stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.

Product Name : Beyonttra

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 28, 2025

blank

Details:

Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: Beyonttra

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2025

blank

04

IFT FIRST
Not Confirmed
IFT FIRST
Not Confirmed

Details : Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.

Product Name : Beyonttra

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 27, 2025

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

IFT FIRST
Not Confirmed
arrow
arrow
IFT FIRST
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

Brand Name : ATTRUBY

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 356MG BASE

Packaging :

Approval Date : 2024-11-22

Application Number : 216540

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

IFT FIRST
Not Confirmed
arrow
arrow
IFT FIRST
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

Brand Name : ATTRUBY

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 356MG BASE

Approval Date : 2024-11-22

Application Number : 216540

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 10880

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/20/3084731/0/en/Acoramidis-Reduced-Incidence-of-Atrial-Fibrillation-Events-in-Patients-with-ATTR-CM.html

GLOBENEWSWIRE
20 May 2025

https://www.globenewswire.com/news-release/2025/05/19/3084268/0/en/Early-and-Sustained-Increase-in-Serum-TTR-Levels-by-Acoramidis-Independently-Predicted-Improved-Survival-in-the-ATTRibute-CM-Study.html

GLOBENEWSWIRE
19 May 2025

https://www.globenewswire.com/news-release/2025/05/13/3079989/0/en/First-Participant-Dosed-with-Acoramidis-in-ACT-EARLY-the-First-Ever-ATTR-Primary-Prevention-Study.html

GLOBENEWSWIRE
13 May 2025

https://www.globenewswire.com/news-release/2025/04/28/3068975/0/en/BEYONTTRA-acoramidis-the-First-Near-complete-TTR-Stabilizer-90-Approved-by-the-UK-Medicines-and-Healthcare-Products-Regulatory-Agency-to-Treat-ATTR-CM.html

GLOBENEWSWIRE
28 Apr 2025

https://www.globenewswire.com/news-release/2023/08/27/2732246/0/en/BridgeBio-presents-detailed-positive-results-from-Phase-3-ATTRibute-CM-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-ATTR-CM-at-European-Society-of-Car.html

GLOBENEWSWIRE
27 Aug 2023

https://www.fiercebiotech.com/biotech/bridgebio-heart-disease-drug-vindicated-phase-3-victory-plots-fda-submission-23

Max Bayer FIERCE BIOTECH
17 Jul 2023

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 2242751-53-5 / Acoramidis Hydrochloride API manufacturers, exporters & distributors?

Acoramidis Hydrochloride manufacturers, exporters & distributors 1

12

PharmaCompass offers a list of Acoramidis Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acoramidis Hydrochloride manufacturer or Acoramidis Hydrochloride supplier.

PharmaCompass also assists you with knowing the Acoramidis Hydrochloride API Price utilized in the formulation of products. Acoramidis Hydrochloride API Price is not always fixed or binding as the Acoramidis Hydrochloride Price is obtained through a variety of data sources. The Acoramidis Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Acoramidis Hydrochloride

Synonyms

Ag10 hydrochloride, Ag-10 hydrochloride, Alxn2060 hydrochloride, Acoramidis (hydrochloride), Alxn-2060 hydrochloride, Vy9c88c2nv

Cas Number

2242751-53-5

Unique Ingredient Identifier (UNII)

VY9C88C2NV

Acoramidis Hydrochloride Manufacturers

A Acoramidis Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acoramidis Hydrochloride, including repackagers and relabelers. The FDA regulates Acoramidis Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acoramidis Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Acoramidis Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Acoramidis Hydrochloride Suppliers

A Acoramidis Hydrochloride supplier is an individual or a company that provides Acoramidis Hydrochloride active pharmaceutical ingredient (API) or Acoramidis Hydrochloride finished formulations upon request. The Acoramidis Hydrochloride suppliers may include Acoramidis Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Acoramidis Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Acoramidis Hydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Acoramidis Hydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Acoramidis Hydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Acoramidis Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Acoramidis Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Acoramidis Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Acoramidis Hydrochloride suppliers with NDC on PharmaCompass.

Acoramidis Hydrochloride GMP

Acoramidis Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Acoramidis Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Acoramidis Hydrochloride GMP manufacturer or Acoramidis Hydrochloride GMP API supplier for your needs.

Acoramidis Hydrochloride CoA

A Acoramidis Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Acoramidis Hydrochloride's compliance with Acoramidis Hydrochloride specifications and serves as a tool for batch-level quality control.

Acoramidis Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Acoramidis Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Acoramidis Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Acoramidis Hydrochloride EP), Acoramidis Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acoramidis Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty